How many insider trades does FilingIQ track for CVKD?

FilingIQ tracks 45 Form 4 insider transactions for CVKD (Cadrenal Therapeutics, Inc.), covering filings from Jan 24, 2023 onwards. 4 of those were filed in the last 90 days.

Are CVKD insiders net buyers or net sellers?

Across the full Form 4 history for CVKD, 11 transactions (24%) were open-market purchases and 27 (60%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CVKD insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CVKD in?

Cadrenal Therapeutics, Inc. (CVKD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $12.67M.

CVKD insider trading

NasdaqCM Healthcare

Cadrenal Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

24% / 60%

Market cap

$12.67M

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Company website: www.cadrenal.com

CVKD insider activity at a glance

FilingIQ has scored 45 insider transactions for CVKD since Jan 24, 2023. The most recent filing in our index is dated May 28, 2026.

Across the full history, 11 open-market purchases and 27 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CVKD insider trades is 59.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CVKD trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,265

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 195

Guardant Health, Inc.

ADPT 184

Adaptive Biotechnologies Corp

BMY 182

BRISTOL MYERS SQUIBB CO

VTRS 165

Viatris Inc

ALNY 153

ALNYLAM PHARMACEUTICALS, INC.

Frequently asked

How many insider trades does FilingIQ track for CVKD?: FilingIQ tracks 45 Form 4 insider transactions for CVKD (Cadrenal Therapeutics, Inc.), covering filings from Jan 24, 2023 onwards. 4 of those were filed in the last 90 days.
Are CVKD insiders net buyers or net sellers?: Across the full Form 4 history for CVKD, 11 transactions (24%) were open-market purchases and 27 (60%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CVKD insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CVKD in?: Cadrenal Therapeutics, Inc. (CVKD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $12.67M.

Methodology & sources

Every CVKD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.